Study highlights new drug, molecular insight into triple negative breast cancers

April 10, 2014

Most breast cancers are treated by blocking their addictions, for example depriving estrogen-fueled tumors of estrogen. But what about breast cancers without these hormonal addictions? In so-called "triple negative" tumors the cancer's addiction remains a mystery, making this subtype difficult to treat. However, a University of Colorado Cancer Center study presented today at the American Association for Cancer Research (AACR) Annual Meeting 2014 showcased a new drug active against triple-negative breast cancer, and through analysis of the drug's mechanism of action, offers increased understanding of the biology of this very aggressive form of breast cancer.

"We developed the compound AMPI-109 in collaboration with Dr. Rahul Ray, a synthetic organic chemist at the Boston University School of Medicine, and showed its effectiveness in preliminary studies of renal and prostate cancers. But it seemed initially as if the drug was inactive against ," says James R. Lambert, PhD, investigator at the CU Cancer Center and assistant research professor at the CU School of Medicine.

However, the initial test of AMPI-109 had been performed against only one form of breast cancer and this disease is notoriously heterogeneous. Despite initial negative results, the group decided to investigate the drug's efficacy against a panel of all known breast cancer subtypes. Strikingly, Lambert and colleagues found the drug was especially effective in specifically one subtype: , in which the drug blocked the growth of cells by greater than 50 percent.

"This was exciting," Lambert says, "not only did we have a drug that potentially targeted triple-negative breast cancer, but we had a biochemical tool that could be used to dissect the molecular underpinnings of the disease. "

To begin to investigate the molecular mechanism of AMPI-109 action in triple negative breast cancer, the group performed a genome-wide functional genetic screen, individually turning off every gene in the cell while exposing the cells to the drug. Identification of the silenced genes in cells that survived drug treatment would show which genes are essential for the drug's cell-killing effect.

"The number one candidate gene from that experiment, performed in collaboration with Dr. Christopher Porter, assistant professor at the CU School of Medicine, was the gene PTP4A3, a gene already implicated as an oncogene in colorectal and liver cancer," Lambert says. He suggests the current study is the first description of PTP4A3 as a potential oncogene in the context of triple-negative breast cancer.

Further work by the lab's graduate student, Hamid Gari, used computer modeling to explore the potential interaction of the PTP4A3 protein with the drug AMPI-109. Sure enough, Gari's modeling, in addition to biochemical experiments, showed that AMPI-109 binds to the catalytic site of the PTP4A3 protein and impairs its ability to function, offering the first evidence that this newly discovered triple-negative breast cancer oncogene may be targetable with AMPI-109.

"But we also wanted to study the effects of blocking PTP4A3 function in the cell," says Gari. When the group directly knocked down expression of the PTP4A3 gene in triple-negative , they saw a 48 percent reduction in cell growth and a drastic reduction in the cancer cells' ability to migrate, a characteristic often acquire in order to spread throughout the body, or metastasize.

"Not only do our data identify PTP4A3 as a potential oncogene in triple negative breast cancer, but it also offers the first reported evidence that AMPI-109 prevents the growth and migratory capability of triple negative breast cancers by targeting PTP4A3. Additionally, this has important clinical implications because we may be able to use PTP4A3 protein levels as a predictive marker to determine which patients may best respond to treatment with AMPI-109," said Gari.

"If PTP4A3 is an oncogenic driver of , and if our inhibits it by this mechanism, this could have strong clinical importance for the population of the people with this disease, for whom treatment has been especially challenging," Lambert says.

Explore further: New finding points to potential options for attacking stem cells in triple-negative breast cancer

Related Stories

New finding points to potential options for attacking stem cells in triple-negative breast cancer

February 17, 2014
New research from the University of Michigan Comprehensive Cancer Center and Georgia Regents University finds that a protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase ...

Paragazole excels in preclinical models of triple-negative breast cancer

April 8, 2013
Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative breast ...

Additional drug shows promise for women with triple-negative breast cancer

December 13, 2013
In a nationwide study of women with "triple-negative" breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of ...

Gene implicated in progression and relapse of deadly breast cancer

March 24, 2014
Scientists from Weill Cornell Medical College and Houston Methodist have found that a gene previously unassociated with breast cancer plays a pivotal role in the growth and progression of the triple negative form of the disease, ...

Smoking linked with increased risk of most common type of breast cancer

February 10, 2014
Young women who smoke and have been smoking a pack a day for a decade or more have a significantly increased risk of developing the most common type of breast cancer. That is the finding of an analysis published early online ...

Integrin cell adhesion receptors are risky cancer drug targets

February 11, 2014
A possible cancer treatment strategy might in fact lead to increased metastasis in some cases. This finding from a team of LACDR researchers led by Erik Danen made the cover of the February 11 edition of Science Signaling.

Recommended for you

Vitamin C may encourage blood cancer stem cells to die

August 17, 2017
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.